Psoriasis exacerbation after COVID-19 vaccines: A brief report of the reported cases

Amr Ehab El-Qushayri*, Beatrice Nardone

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Despite the significant reduction of both morbidity and mortality after the introduction of many vaccines against COVID-19, recent reports indicated a worsening skin conditions in particular patients with psoriasis. We extracted the data of 51 patients from 19 papers. The mean age was 56.9 (SD = 16.2) years, with a male prevalence 45%. Of the 51 cases, vaccine types at which psoriasis flare occurred were as the following: Pfizer vaccine (30), AstraZeneca (9), Moderna (8), Coronavac (2) Covishield (1), and Covaxin (1). Exacerbation was common in the second dose of Pfizer, AstraZeneca, Moderna, and Covishield vaccines. Moreover, the onset of psoriasis exacerbation was shorter after the second dose of Pfizer (mean = 12.8 [SD = 15.2]) and AstraZeneca (mean = 7.4 [SD = 3.6]) rather than the first dose of both vaccines, respectively (mean = 19.2 [SD = 21.3]) and (mean = 18.5 [SD = 10.7]).

Original languageEnglish (US)
Article numbere15900
JournalDermatologic Therapy
Issue number12
StatePublished - Dec 2022


  • COVID-19 vaccine
  • COVID-19 vaccines
  • exacerbation
  • flare
  • psoriasis

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Psoriasis exacerbation after COVID-19 vaccines: A brief report of the reported cases'. Together they form a unique fingerprint.

Cite this